22
Infectious mononucleosis (IM) and Epstein-Barr virus (EBV) For Third- Year Medical Students Dr: Hussein Mohammed Jumaah CABM Mosul Medical College 31/3/2014

Infectious mononucleosis (im) and epstein barr virus

Embed Size (px)

Citation preview

Page 1: Infectious mononucleosis (im) and epstein barr virus

Infectious mononucleosis (IM) and Epstein-Barr

virus (EBV)

For Third- Year Medical StudentsDr: Hussein Mohammed JumaahCABMMosul Medical College31/3/2014

Page 2: Infectious mononucleosis (im) and epstein barr virus

EBV is a gamma herpes virus. In developing countries, subclinical

infection in childhood is virtually universal.

In developed countries, primary infection may be delayed until early adult life.

The virus is acquired from asymptomatic excreters via saliva, by droplet infection, or by kissing.

EBV is not highly contagious ,isolation is unnecessary.

Infectious mononucleosis (IM) and Epstein-Barr virus (EBV)

Page 3: Infectious mononucleosis (im) and epstein barr virus

Infectious mononucleosis (IM) and Epstein-Barr virus (EBV)

IM is an acute viral illness characterised by fever , pharyngitis, cervical lymphadenopathy, and lymphocytosis.

Whereas ~90% of cases of IM are due to EBV,

5–10% of cases are due to Cytomegalovirus (CMV).

CMV is the most common cause of heterophile-negative mononucleosis.

Less common causes rubella ,Toxoplasma, HIV, herpesvirus 6, hepatitis viruses and drug reactions.

Page 4: Infectious mononucleosis (im) and epstein barr virus

Clinical features

IM has a prolonged and undetermined incubation period, followed by a prodrome of fever, headache and malaise, succeeded by IMwith severe pharyngitis, which may include tonsillar exudates, and non-tender cervical lymphadenopathy. Palatal petechiae, periorbital oedema, splenomegaly, macular, petechial or erythema multiforme rashes may occur.

Page 5: Infectious mononucleosis (im) and epstein barr virus

In most cases fever resolves over 2 weeks, and other abnormalities settle over a further few weeks. EBV may present with jaundice, PUO* or with a complication.Death is rare but can occur due to 1. Respiratory obstruction. 2. Haemorrhage (splenic rupture or thrombocytopenia).3. Encephalitis. *pyrexia of unknown origin

Clinical features

Page 6: Infectious mononucleosis (im) and epstein barr virus

Complications of Epstein–Barr virusn infection

Page 7: Infectious mononucleosis (im) and epstein barr virus

In children under 10 years the illness is

mild and short-lived, but in adults over

30 years of age it can be severe and

prolonged. Investigations Atypical lymphocytes are

common in EBVinfection but also occur in

other causes of IM, HIV infection,

viral hepatitis, mumps and rubella.

The most commonly used diagnostic

criteria is the presence of 50%

lymphocytes. (at least 10% atypical) .

Atypical lymphocytes.

enlarged lymphocytes that have abundant cytoplasm, vacuoles, and indentations of the cell membrane .

Diagnosis

Page 8: Infectious mononucleosis (im) and epstein barr virus

A 'heterophile' antibody is present during the acute illness and convalescence, agglutinates erythrocytes of other species, e.g. sheep and horse. detected by the classical Paul-Bunnell titration or a more convenient slide test such as the'Monospot'.

Investigations

Page 9: Infectious mononucleosis (im) and epstein barr virus

Specific EBV serology (immunofluorescence) can be used to confirm the diagnosis if necessary. Acute infection is characterised by IgM antibodies against the viral capsid, antibodies to EBV early antigen and the initial absence of antibodies to EBV nuclear antigen (anti-EBNA). Seroconversion of anti-EBNA at approximately1 month after the initial illness may confirm the diagnosis in retrospect. CNS infections may be diagnosed by detection of viral DNA in cerebrospinal fluid.

Investigations

Page 10: Infectious mononucleosis (im) and epstein barr virus

Management

largely symptomatic. If a throat culture yields

aβ-haemolytic streptococcus, a course of penicillin should be prescribed. ampicillin or amoxicillin in this condition commonly causes an itchy macular rash, and should be avoided.

When pharyngeal oedema is severe, a short course of corticosteroids, e.g. prednisolone 30 mg daily for 5 days, may help.

Antivirals are not sufficiently active against EBV.

Page 11: Infectious mononucleosis (im) and epstein barr virus

Return to work or school is governed by the patient's physical fitness. contact sports should be avoided until splenomegaly has completely resolved because of the danger of splenic rupture.

10% of patients with IM suffer a chronic relapsing syndrome.

Page 13: Infectious mononucleosis (im) and epstein barr virus

After initial infection ,Varicella zoster virus ,(VZV) persists in latent form in the dorsal root ganglion of sensory nerves and can reactivate in later life as a localised rash or with other clinical manifestations. Commonly seen in the elderly,

shinglesmay also present in younger

patientswith immune deficiency. Chickenpox may be

contracted from acase of shingles but not

vice versa.It is not clear why this

happens.

Shingles (herpes zoster)

Page 14: Infectious mononucleosis (im) and epstein barr virus

Clinical features

Burning discomfort occurs in the affected dermatome, where discrete vesicles appear 3-4 days later, associated with a brief viraemia and can produce distant satellite 'chickenpox' lesions. Severe disease, a prolonged duration of rash, multiple dermatomal involvement or recurrence suggests underlying immune deficiency.

Clinical features

Page 15: Infectious mononucleosis (im) and epstein barr virus

Thoracic dermatomes are most

Commonly involved .Ophthalmic division of the trigeminal nerve is also

frequently affected;vesicles may appear

on the cornea and lead to

ulceration,andcan lead to blindness. Bowel and bladder

dysfunction occur with sacral nerve root involvement.The virus occasionally

causes myelitis or encephalitis.

Clinical features

Page 16: Infectious mononucleosis (im) and epstein barr virus

Ramsay Hunt syndromeInvolvement of the Geniculate ganglion causes facial palsy, ipsilateral loss of taste and buccal ulceration, plus a rash in the external auditory canal. This may be mistaken for Bell's palsy. Post-herpetic neuralgiaPostherpetic neuralgia arises in approximately 20% of patients . Troublesome persistence of pain for 1-6 months or longer, following healing of the rash. It is more common with advanced age.

Clinical features

Page 17: Infectious mononucleosis (im) and epstein barr virus

Management and prevention Aciclovir has been shown to reduce both early- and late-onset pain. new drugs valaciclovir and famciclovir . demonstrate similar or superior efficacy and good safety and tolerability.Post-herpetic neuralgia requires aggressive analgesia, along with agents such as amitriptyline or gabapentin. Capsaicin cream may be helpful. Although controversial, corticosteroids have not been demonstrated to reduce post-herpetic neuralgia to date.

Page 18: Infectious mononucleosis (im) and epstein barr virus

Acyclovir for chickenpox/shinglesAciclovir shortens symptoms in chickenpox by an average of 1 day. In shingles aciclovir reduces pain by 10 days and the risk of post-herpetic neuralgia by 8%. Aciclovir is therefore cost-effective in shingles but not chickenpox.'

Page 19: Infectious mononucleosis (im) and epstein barr virus

Human VZ immunoglobulin (VZIG) is used to attenuate infection in people who have had significant contact with VZV, are susceptible to infection (i.e. have no history of chickenpox or shingles and are negative for serum VZV IgG) and are at risk of severe disease (e.g. immunocompromised, steroid-treated or pregnant). Newborn whose mother develops chickenpox no more than 5 days before delivery or 2 days after delivery.Ideally, VZIG should be given within 7 days of exposure, but it may attenuate disease even if given up to 10 days afterwards. Susceptible contacts who develop severe chickenpox after receiving VZIG should be treated with aciclovir.

Page 20: Infectious mononucleosis (im) and epstein barr virus

A zoster vaccine (Zostavax) ,VZV vaccine ,.Is a live, attenuated . Is exceedingly safe ,On March 24, 2011, the Food and Drug Administration (FDA) approved its use for the prevention of shingles in individuals 50 to 59 years of age, including persons who have already had an episode of shingles. should not be given to individuals who have a. A weakened immune system b. Individuals with active, untreated

tuberculosis. c. Pregnant women should not receive

this vaccine.

Page 21: Infectious mononucleosis (im) and epstein barr virus

UK ,its use has been restricted to non-immune healthcare workers and household contacts of immunocompromised individuals. Children receive one dose after 1 year of age and a second dose at 4–6 years of age; seronegative adults receive two doses at least 1 month apart. The vaccine may also be used prior to plannediatrogenic immunosuppression, e.g. before transplant.

Page 22: Infectious mononucleosis (im) and epstein barr virus